晚期多形性横纹肌肉瘤系统治疗结局:PUSH联盟回顾性研究
中位随访44个月,中位OS-1和PFS-1分别为13.6和5.4个月;蒽环类方案ORR 50%,吉西他滨类方案ORR 42%,帕唑帕尼ORR 33%,PD-1抑制剂2例中1例缓解持续53个月。
要点
- 蒽环类方案在晚期P-RMS中显示最高ORR(50%),中位PFS-2为5.2个月。
- 吉西他滨类方案ORR 42%,中位OS-2为7.8个月,可作为治疗选择。
- 帕唑帕尼和PD-1抑制剂显示个别应答,需前瞻性验证。
核心结论
- 晚期P-RMS对蒽环类和吉西他滨类方案有显著活性,帕唑帕尼和PD-1抑制剂可见个别应答。
主要发现
- 中位随访44个月(IQR 17.0-74.8),49例(64%)死亡,48例(62%)进展。
- 中位OS-1为13.6个月(95%CI 9.4-22.5),中位PFS-1为5.4个月(95%CI 4.2-7.3)。
- 2年和3年OS-1分别为32.5%和30.3%。
- 蒽环类方案(n=42)ORR 50%,中位PFS-2和OS-2分别为5.2和19.2个月。
- 吉西他滨类方案(n=15)ORR 42%,中位PFS-2和OS-2分别为3.7和7.8个月;帕唑帕尼(n=6)ORR 33%,中位PFS-2和OS-2分别为2.4和4.2个月;PD-1抑制剂(n=2)中1例缓解持续53个月。
临床怎么用
- 蒽环类方案可作为晚期P-RMS的首选系统治疗选择之一。
- 吉西他滨类方案可作为替代选择,尤其在不适合蒽环类时。
- 帕唑帕尼和PD-1抑制剂可在个体化决策中考虑,但需更多证据。
局限性
- 回顾性研究设计,存在选择偏倚和信息偏倚。
- 缺乏前瞻性验证,结论需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the outcomes in adult patients with advanced pleomorphic rhabdomyosarcoma (P-RMS) treated with systemic therapy. METHODS: This global, multicenter, retrospective study conducted within the Pushing Ultra-Rare Sarcomas Towards Hope consortium (PUSH) included patients > 40 years with histologically confirmed advanced P-RMS, treated with at least one line of systemic therapy between 2013 and 2023. The primary endpoint was progression-free survival from first diagnosis of advanced disease, and from systemic treatment start (PFS-1 and PFS-2). Secondary endpoints included overall response rate (ORR), overall survival from first diagnosis of advanced disease and from treatment start (OS-1 and OS-2), and treatment-specific outcomes. RESULTS: Seventy-seven patients were included from 21 sarcoma reference centers. At a median follow-up of 44 months (IQR: 17.0-74.8), 49 (64%) patients had died and 48 (62%) had progressed. The median OS-1 and PFS-1 were 13.6 (95% confidence interval (CI): 9.4-22.5) and 5.4 (95% CI: 4.2-7.3) months, respectively. Two- and three-year OS-1 were 32.5% and 30.3%. Anthracycline-based regimens (n = 42) achieved a 50% ORR, with mPFS-2 and mOS-2 of 5.2 and 19.2 months; gemcitabine-based regimens (n = 15) a 42% ORR, with mPFS-2 and mOS-2 of 3.7 and 7.8 months; pazopanib (n = 6) a 33% ORR, with mPFS-2 and mOS-2 of 2.4 and 4.2 months; PD-1 inhibitors (n = 2) induced one response lasting 53 months. CONCLUSIONS: This series of advanced P-RMS treated with systemic agents, the largest available to date, showed meaningful activity of anthracycline- and gemcitabine-based regimens, and anecdotal responses to pazopanib and PD-1 inhibitors. Further prospective validation is planned.
引用
- Baldi GG, Giani C, Ljevar S, et al. Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium. Eur J Cancer. 2026. PMID: 41819027. doi:10.1016/j.ejca.2026.116666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。